BioSpace News Archive

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, honors National Muscular Dystrophy Awareness Month, an annual observance that raises awareness for families across the nation who are living with neuromuscular diseases.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that their previously mentioned Advance Safety Needle System™ has entered full scale production on their automated machine.

Isofol Medical AB, reported data from the AGENT study that formed the basis for its assessment that it was not justified to continue the study.

“We are excited to announce the addition of two new target indications for batoclimab, one of which will be a pivotal program, confirming our confidence in the broad development opportunity for batoclimab,” said Pete Salzmann, M.D., Chief Executive Officer of Immunovant.

Rebranding aligns core Biosynth Group members across Complex Chemical and Peptide Manufacturing Services and Catalog Business.

ViewRay, Inc. announced that the company’s MRIdian MRI-Guided Radiation Therapy System has received approval from the Chinese regulatory authority National Medical Products Administration, allowing for its sale and utilization throughout China.

Nuvalent, Inc. announced it will present preliminary dose escalation data from its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors during an oral plenary session at the 34th EORTC-NCI-AACR Symposium taking place October 26-28, 2022 in Barcelona, Spain.

BioNTech SE announced that Prof. Ugur Sahin, CEO and Co-founder of BioNTech, visited Israel to meet with the Minister of Economy and Industry, Major General Orna Barbivay, the Accountant General, Mr. Yali Rothenberg, and other government officials.

Zealand Pharma A/S announced it has entered into a global license and development agreement with Novo Nordisk A/S to commercialize ZEGALOGUE® for injection.

Biophytis SA released top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.